

ELENCO PRINCIPALI PUBBLICAZIONI

- 1) PM PIATTI, LD MONTI, M CONTI, E FOCESATO, CV PHAN, L BARUFFALDI, G SANTAMBROGIO, R NASSER, **B GUAZZINI**, M BRUCIAFERRI, C STANGALINI, AE PONTIROLI, G POZZA.

Effects of increased insulin and triglyceride levels on endothelin-1 release.

Fontiers in Endocrinology, 15: 63-66, 1995.

- 2) PM PIATTI, LD MONTI, M CONTI, L BARUFFALDI, L GALLI, CV PHAN, **B GUAZZINI**, AE PONTIROLI, G POZZA.

Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans.

Diabetes, 45: 316-320, 1996.

- 3) PM PIATTI, LD MONTI, G VALSECCHI, MCONTI, R NASSER, **B GUAZZINI**, E FOCESATO, CV PHAN, AE PONTIROLI, G POZZA.

Effects of low dose heparin infusion on arterial endothelin-1 release in man.

Circulation, 94:2703-2707, 1996.

- 4) **B GUAZZINI**, D GAFFI, D MANIERI, G MULTARI, R CORDERA, S BERTOLINI, G POZZA, F MESCHI, F BARBETTI.

Three novel missense mutations in the glucokinase gene (G80S; E221K; G227C) in Italian subjects with maturity-onset diabetes of the young (MODY).

Human mutation. On line.

- 5) M. GIUSTI, R. ZOCCOLA, **B. GUAZZINI**, E. MOLINARI, S. VALENTI, G. VILLA, L. BERTOLAZZI, F. MINUTO.

Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.

Minerva endocrinologica, 28 (n 3): 191-203, 2003.

- 6) M. BEVILACQUA, **B. GUAZZINI**, V. RIGHINI, M. BARRELLA, R. TOSCANO, E. CHEBAT.
Metabolic effects of Fluvastatin extended release 80 mg and Atorvastatin 20 mg in patients with type 2 Diabetes Mellitus and low serum high density lipoprotein cholesterol levels: A 4 month, prospective, open-label, randomized, blinded-end point (probe) Trial.

Current Therapeutic Research, 65 (n 4):1-12, 2004.

- 7) M. CERABINO, R. GHELARDI, **B. GUAZZINI**, S. ZARKADAS, M. SPINA

Caso clinico: neuropatia, sintomo di esordio del diabete, regredita rapidamente con il normalizzarsi della glicemia.

Boll Soc Med Chir Pavia 2006, 119: 677-684.

Abstracts.

- 1) PM PIATTI, LD MONTI, L BARUFFALDI, G SANTAMBROGIO, M CONTI, R NASSER, **B GUAZZINI**, E FOCESATO, MC LIBRENTI, AE PONTIROLI, G POZZA.

Effects of increased insulin and trygliceride levels on endothelin-1 release.

International symposium on Endothelins in endocrinology: new advances CO7:1994.

- 2) PM PIATTI, A CAUMO, E CUCCHI, LD MONTI, C ORENA, R NASSER, M BRUCIAFERRI, **B GUAZZINI**, E FOCESATO, MC LIBRENTI, G POZZA, AE PONTIROLI..

Effects of on acute lowering of free fatty acids levels on insulin and glucose affectiveness in visceral and subcutaneous obesity.

European Journal of Clinical Investigation, 25 (suppl.2): 314,1995.

- 3) LD MONTI, A CAUMO, P PIATTI, E CUCCHI, C ORENA, M CONTI, **B GUAZZINI**, MC LIBRENTI, G POZZA, AE PONTIROLI.

Differential effects of free fatty acid levels on insulin sensitivity and glucosse effectiveness in visceral and subcutaneous obesity.

Diabetes 44:203 A,1995.

- 4) PM PIATTI, LD MONTI, A CAUMO, G SANTAMBROGIO, M CONTI, G VALSECCHI, L BARUFFALDI, EP SANDOLI, **B GUAZZINI**, AE PONTIROLI, G POZZA.

Insulin and proinsulin release after intravenous glucose challenge in subjects with insulinoma.

Diabetologia 38 (suppl. 1):433,1995.

- 5) PM PIATTI, LD MONTI, **B GUAZZINI**, CV PHAN, E FOCESATO, C CUSIN, AE PONTIROLI, G POZZA.

Can an acute or a chronic hyperinsulinemia and hypertriglyceridemia increase endothelin-1 release in man?

Acta Diabetologica 33:81,1996.

- 6) M CONTI, PM PIATTI, LD MONTI, **B GUAZZINI**, L BARUFFALDI, CV PHAN, E FOCESATO, G POZZA, AE PONTIROLI.

Triglycerides and insulin are inducers of endothelin-1 release: a new approach in the pathogenesis of cardiovascular disease in subjects affected by plurimetabolic syndrome (Syndrome X).

European Journal of clinical Investigation 26 (suppl.1):227,1996.

- 7) **B GUAZZINI**, PM PIATTI, LD MONTI, G SANTAMBROGIO, G VALSECCHI, VC PHAN, E FOCESATO, C STANGALINI, C CUSIN, G POZZA, AE PONTIROLI.

Insulin induces an acute endothelin-1 but not nitric oxide release in hypertensive subjects.

European Journal of Clinical investigation 25 suppl.1:237,1996.

- 8) PM PIATTI, LD MONTI, **B GUAZZINI**, L GALLI, CV PHAN, S COSTA, AE PONTIROLI, G POZZA.

Ruolo dei trigliceridi e dell'insulina nella secrezione di endotelina-1 nell'uomo.

Diabete 46 suppl.1:39, 1996.

9) D GAFFI, **B GUAZZINI**, D MANIERI, G MULTARI, R CORDERA, S BERTOLINI, G MESCHI, G POZZA, F BARBETTI.

Three mutations in the Glucokinase Gene in Italian Subjects with Maturity-Onset-Diabetes of the young (MODY).

Diabetes 46 suppl.1:176 A,1997.

10)PM PIATTI, LD MONTI, G VALSECCHI, CV PHAN, **B GUAZZINI**,L BARUFFALDI, B DALLAGRASSA, M CONTI, E FOCESATO, G POZZA, AE PONTIROLI.

Relationship between hypertriglyceridemia and increased endothelin-1 and blood pressure levels in subjects with plurimetabolic syndrome.

4th International Symposium on Multiple Risk Factors in cardiovasclar Disease, 1997.

11)PM PIATTI, G FRAGASSO, LD MONTI, **B GUAZZINI**, B DALLA GRASSA, VC PHAN, G VALSECCHI, E FOCESATO, A PIZZINI, C STANGALINI, S CHIERCHIA, G POZZA, AE PONTIROLI.

New insight in the pathogenesis of angina and angiographically normal coronary arteries.

4th International Symposium on Multiple Risk Factors in cardiovasclar Disease, 1997.

12)PM PIATTI, A CAUMO, LD MONTI, **B GUAZZINI**, B DALLAGRASSA, G VALSECCHI, E FOCESATO, APIZZINI, G POZZA, AE PONTIROLI.

Influence of free-testosterone in the modulation of glucose effectiveness in obese women.

79th Annual Meeting, Minneapolis, The Endocrine Society: P2-524,1997.

13)M CONTI, PM PIATTI, A CAUMO, LD MONTI, **B GUAZZINI**,B DALLAGRASSA, G VALSECCHI,E FOCESATO, A PIZZINI, G POZZA, AE PONTIROLI.

Relationship between free-testosterone levels and glucose affectiveness after an acute decrease in FFA levels in obese women.

Diabetologia 40 suppl.1:966,1997.

14)PM PIATTI, LD MONTI, G VALSECCHI,CV PHAN, **B GUAZZINI**, L BARUFFALDI,B DALLAGRASSA, E FOCESATO, A PIZZINI, AE PONTIROLI, G POZZA.

Hypertriglyceridemia is an indipendent predictor of elevated endothelin-1 and blood pressure levels in subjects with plurimetabolic syndrome.

Diabetologia 440 suppl.1:70,1997.

15)**B GUAZZINI**, D MANIERI, G MULTARI, R CORDERA, S BERTOLINI, R BONFANTI, F MESCHI, F BARBETTI.

Search for mutations in the genes encoding for Glucokinase (MODY2) and Hepatocyte Nuclear factor 1 α (MODY3) and 4 α (MODY1) in Italian Subjects with MODY.

J Endocrinol Invest suppl., 1997.

16) **B GUAZZINI**, D MANIERI, G MULTARI, R CORDERA, S BERTOLINI, R BONFANTI,F MESCHI, G CHIUMELLO, F BARBETTI.

Ricerca di mutazioni nei geni codificanti la glucochinasasi e gli Hepatocyte nuclear factor 1 alfa e 4 alfa in pazienti italiani con MODY.

Minerva pediatrica,1997.

- 17) A DE PASCALE, A GALLO, V CHELI, **B GUAZZINI**, P MELGA, M SCHIAVO.
RMN e radiografia tradizionale nella diagnosi di osteomielite in pazienti con ulcere diabetiche.
Diabete Vol.12,suppl 1, Marzo 2000.
- 18)S VALENTI, **B GUAZZINI**, D CAVALLERO, S GARRONE, L FAZZUOLI, M GIUSTI.
Valutazione dei livelli di Ossido Nitrico in liquidi di noduli cistici tiroidei ottenuti con agoaspirato.
Diciottesime giornate italiane della tiroide (Agrigento , Dicembre2000).
- 19)S VALENTI, **B GUAZZINI**, L FAZZUOLI, M GIUSTI.
Testosterone preserves mitochondrial respiration rat Leydig Cells exposed to lipopolysaccharide in vitro.
Andrology in the 21stCentury, Montreal,Quebec, June 15-19, 2001.
- 20)M. GIUSTI, G. VILLA, R. ZOCCOLA, **B. GUAZZINI**, E. MOLINARI, L. BERTOLAZZI, F. MINUTO.
Serum thyroglobulin and 131-I whole body scintigraphy after recombinant human TSH and 99-TC- sestamibi in the management of differentiated thyroid carcinoma.
The endocrine society's 83rd annual meeting, Denver, June 20-23, 2001.
- 21)G. VILLA, M. GIUSTI, R. ZOCCOLA, **B. GUAZZINI**, E. MOLINARI, F. CASTAGNOLA, L. BERTOLAZZI, F. MINUTO.
Management of differentiated thyroid carcinoma by serum thyroglobulin and 131 I scintigraphy after recombinant human TSH and 99mtc-sestamibi.
European Journal of Nuclear Medicine, 28/8,2001.
- 22)M. BEVILACQUA, **B. GUAZZINI**, V. RIGHINI, M. BARRELLA, R. TOSCANO, E. CHEBAT.
Gli effetti metabolici della somministrazione di fluvastatina (80mg RP)nei diabetici di tipo 2 selezionati per bassi livelli di colesterolo HDL sono differenti.
Il Diabete, suppl.al n.1 ,vol.16, Marzo 2004.